H&E staining showed reduced tumor cellularity following the combination therapy, and measurements of Ki-67 expression showed a 68% reduction for B+A combined therapy, compared with a 13% reduction for bevacizumab monotherapy and a 39% reduction for anlotinib monotherapy (Figures 5D, E). The gene discussed is MKI67; the disease is neoplasm.